8-K filing — CERENOME, INC. (CNSY)
Filed: 2026-11-16 AccNo: 0001193125-26-462116 Size: 211 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Cerenome, Inc. will host a conference call on November 16, 2026, to review clinical data for its lead therapeutic candidate, REYOBIQ, and provide a commercial update on its CNSide diagnostic platform.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-16 AccNo: 0001193125-26-462116 Size: 211 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Plus Therapeutics, now operating as Cerenome, announced the completion of enrollment in its Phase 2 glioblastoma trial and provided interim data for its REYOBIQ™ leptomeningeal metastases program.
Cerenome (Nasdaq: CNSY) reported Q3 2026 results with $0.7M in net diagnostic revenue from its CNSide CSF assay platform. The company expanded payer coverage to ~190M covered lives including new agreements with Aetna, Medical Mutual, and others. REYOBIQ therapeutic program advanced with completed Phase 2 enrollment in recurrent glioblastoma and positive interim Phase 1 multi-dose data in leptomeningeal metastases showing no dose-limiting toxicities. However, the company reported a net loss of $8.7M and cash position of $4.9M as of September 30, 2026.
Four biotechnology companies presented clinical findings and emerging treatment approaches for brain cancers at the 31st Annual Meeting of the Society for Neuro-Oncology in Philadelphia. NeOnc Technologies is preparing for FDA meetings on two programs (NEO100 and NEO212), Cerenome is advancing REYOBIQ therapy and diagnostic tools, Nuvation Bio is expanding data on safusidenib for IDH1-mutant gliomas, and Jazz Pharmaceuticals is progressing dordaviprone through Phase 3 trials for rare brain cancers.
Gainers Cerenome (NASDAQ:CNSY) shares rose 39.5% to $1.07 during Friday's regular session. The market value of their outstanding shares is at $5.8 million. As per the press release, Q3 earnings came out today. SBC
Cerenome, Inc. has appointed Ron “Ronnie” Andrews to the newly created position of Chief Business Officer, while he continues to serve on the company's Board of Directors.